Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

544 ARTÍCULOS , VIENDO DEL 31 AL 45

Targeting Microglial Transcriptional Reprogramming as a Therapy Strategy for Alzheimer's Disease

Kim B, Wang SS, Kim JR, Kim J.

Bioessays. 2026 Oct;48(10):e70186. doi: 10.1002/bies.70186.

The orexinergic system in Alzheimer's disease: from sleep disruption to accelerated neurodegeneration

Liguori C, Carpi M.

Eur Neurol. 2026 Sep 30:1. doi: 10.1159/ene/acsag009. Online ahead of print.

The immunoproteasome in Alzheimer's disease: a dual regulator of tau pathology and microglial senescence

Shokr MM, Abdelaziz AM.

Inflammopharmacology. 2026 Oct 3. doi: 10.1007/s10787-026-02393-1. Online ahead of print.

Recent advances of GPR40 agonists as potential anti-Alzheimer's agents

da Silva JMA, Kümmerle AE, Rodrigues DA, Bolognesi ML, Milelli A, Lima LM, de Sena Murteira Pinheiro P.

Future Med Chem. 2026 Oct;18(20):2953-2968. doi: 10.1080/17568919.2026.2732260. Epub 2026 Oct 6.

Dysregulated mRNA Translation in Alzheimer's Disease: Mechanisms, Therapeutic Opportunities, and Challenges for Clinical Translation

Li L, Dai F, Liu H, He S, Zhang X, Tao QQ.

Clin Interv Aging. 2026 Oct 2;21:626483. doi: 10.2147/CIA.S626483. eCollection 2026.

From pathogenesis to non-medical therapy: A review of exploring sensory and multi-sensory stimulation as a non-invasive treatment approach for Alzheimer's disease

Zhu Y, Jafari Z, Kolb BE, Mohajerani MH.

Neurosci Biobehav Rev. 2026 Dec;191:107004. doi: 10.1016/j.neubiorev.2026.107004. Epub 2026 Oct 7.

[Research progress on the correlation mechanism between innate immune imbalance and Alzheimer's disease based on Drosophila model]

Chen S, He M, Huo Y, Xing F, Gao Y, Dai Y, Gao N, Yin S.

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2026 Oct;42(10):931-937.

Spatiotemporal heterogeneity and dynamic evolution of microglial glucose metabolic reprogramming in Alzheimer's disease

Chen Y, Li F, Zhang J, Wei M, Ni J, Li T, Yao L, Tian J, Shi J.

Alzheimers Dement. 2026 Oct;22(10):e71909. doi: 10.1002/alz.71909.

Tau phosphorylation from neuronal adaptation to Alzheimer's disease

Trouvé R, Verstreken P, Hoekstra MMB.

Neuron. 2026 Oct 9:S0896-6273(26)00683-5. doi: 10.1016/j.neuron.2026.08.032. Online ahead of print.

Advantage of cerebellar intermittent theta-burst stimulation in Alzheimer's disease (ACT-AD): study protocol for a multicenter, randomized, double-blind, sham-controlled trial

Zhang X, Li W, Sun Z, Wang X, Song C, Wang X, Niu Y, Wei D, Zhang W, Zhang G, Zhang B, Wang L, Liu Z, Zhao J, Jiang W.

Trials. 2026 Oct 9;27(1):601. doi: 10.1186/s13063-026-10009-w.

Gantenerumab reduces brain amyloid-β proteoforms: Biochemical evaluation in dominantly inherited Alzheimer disease

Mukherjee S, Barthélemy NR, Atri T, Li Y, Yen D, He Y, Coyle R, Ovod V, Franklin EE, Xiong C, Wang G, Xu J, Farsad H, Mummery CJ, Masters CL, Sanchez-Valle R, Masellis M, Hsiung GR, Guthier S, Lah JJ, Berman SB, Roberson ED, Surti G, Honig LS, Clarnette R, Vitali P, Ringman J, Bird TD, Brooks WS, Fox NC, Suzuki K, Black SE, Levin J, Farlow MR, Chhatwal J, Aggarwal NT, Jucker M, Frosch MP, Kofler JK, White C 3rd, Keene CD, Chen J, Glass J, Gearing M, Ryan NS, Aguillón D, Supnet-Bell C, Gordon BA, Benzinger TLS, Sims J, Yaari R, Bittner T, Klein G, Delmar P, Morris JC, Llibre-Guerra J, Clifford DB, Karch CM, McDade E, Perrin RJ, Bateman RJ.

medRxiv [Preprint]. 2026 Sep 29:2026.09.22.26363432. doi: 10.64898/2026.09.22.26363432.

Neuroimmune State Configurations at the Amyloid-Tau Interface in Alzheimer's Disease: A Testable Framework

Zhang K, Zhang Y, Jiang X, Chen X.

Aging Dis. 2026 Oct 9. doi: 10.14336/AD.2026.0888. Online ahead of print.

Dementia with Lewy bodies and amyloid pathology: Eligible for anti-amyloid treatment or not?

Exalto LG, van Alphen JL, Barkhof F, Teunissen C, Vijverberg EGB, Aarsland D, Lemstra AW.

Alzheimers Dement. 2026 Oct;22(10):e71907. doi: 10.1002/alz.71907.

Targeting tau acetylation in Alzheimer's disease: Molecular mechanisms, pathological consequences, and therapeutic opportunities of dietary phytochemicals

Basavaraju KC, Priyadarshini P.

Biochem Biophys Res Commun. 2026 Nov 12;839:154717. doi: 10.1016/j.bbrc.2026.154717. Epub 2026 Oct 10.

Immunosenescence as a modifiable driver of neurodegenerative diseases: Pathways and multidimensional emerging strategies for Alzheimer's and Parkinson's diseases

Zhao J, Qu L, Guan H, Che H, Shi F, Yang Y.

Neurotherapeutics. 2026 Oct;23(6):e01096. doi: 10.1016/j.neurot.2026.e01096. Epub 2026 Oct 12.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias